Crowdonomics
WatchlistPortfolio
All companies
REXIS BIOTECH, INC. logo

REXIS BIOTECH, INC.

Operating

Rexis Biotech Inc.

Food & Beverage · Founded 2022

Visit website

Making drinks taste better, your medicine work better & your drugs more fun

Post-money valuation ⓘ
$12.5M
As of Apr 2024 · from Reg CF Offering (2023) · pre-money + amount raised, not a traded price
Total raised
$469,889
Across 1 round since 2023
Latest share price
$1.25
Reg CF · Preferred Stock · Dec 2023 offering price

Financials

FY2021–FY2022 · from SEC filings · hover any figure for its source
$3.1M
$141K
2021
$8.4M
$894K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 unaudited
FY2022 unaudited
Income statement
Revenue
$3,119,575
$8,400,823
Cost of goods sold
$1,293,815
$3,429,923
Gross margin
59%
59%
Net income
$140,884
$893,891
Taxes paid
$33,201
$0
Balance sheet
Cash
$48,195
-$121,220
Accounts receivable
$112,646
$4,565,035
Total assets
$2,509,831
$8,262,782
Short-term debt
$0
$0
Long-term debt
$0
$469,797
Total liabilities
$0
$469,797
Other
Headcount
—
22

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$12.0M
pre-money
Reg CF · Preferred · Dec 2023

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Reg CF · Preferred Stock · Dec 2023Closedvia WeFunder
Raised $469.9K / $1.2MInvestors 214Post-money $12.5M

Team

2 people
Keith Bushfield
CEO
Daniel R Wittmers
Executive Vice President

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 1 of 3 annual reports (FY2023–FY2025)

214 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-ARApr 14, 20250002000970-25-000001
    EDGAR
  • Form CDec 8, 20230001670254-23-001115
    EDGAR
Source: ManualCIK 0002000970Share price $1.25

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.